All the forces in the world are not so powerful as an idea whose time has come.
Not what we were expecting!
When analyzing the results of the first Trial to Assess Chelation Therapy (TACT), researchers found that a subgroup of patients with diabetes who received EDTA chelation had fewer cardiovascular events than patients who did not receive EDTA chelation. This was not what researchers were expecting to find.
An article in the American Heart Association’s journal Circulation: Cardiovascular Quality and Outcomes has the details: The Effect of an EDTA-based Chelation Regimen on Patients With Diabetes Mellitus and Prior Myocardial Infarction in the Trial to Assess Chelation Therapy (TACT)
TACT2 is the second Trial to Assess Chelation Therapy.
A Black Swan Event: The results of the first TACT are something rarely seen in large randomized clinical trials: very unexpected, with possible far-reaching consequences.
In his book “The Black Swan: the Impact of the Highly Improbable,” Nassim Nicholas Taleb termed such occurrences “black swan events,” and convincingly discussed how such events can alter the course of science.
What is TACT2?
TACT2 is a clinical trial to determine whether intravenous (IV) Na2EDTA chelation therapy with oral (by mouth) multivitamins will reduce the risk of major cardiovascular events (such as stroke and heart attack) in patients who have already had a heart attack and who also have type 2 diabetes.
Why is TACT2 important?
If TACT2 finds the same results as TACT1, EDTA chelation therapy may become a novel guideline-supported therapeutic option for patients with coronary artery disease who are already on evidence-based medical therapy.
Who may enroll in TACT2?
Patients who are 50 years old or older, who have had a heart attack, and have diabetes. Eligible participants must meet other eligibility criteria at the time of enrollment.